Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
12 authors.
Iván García de la TorreDepartment of Immunology, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Hospital Universitario Ramón y Cajal, 28034 Madrid, Spain.ORCID 0009-0006-5221-2752
Carlota García-HozDepartment of Immunology, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Hospital Universitario Ramón y Cajal, 28034 Madrid, Spain.ORCID 0000-0001-8268-4159
Fernando Martin-MoroDepartment of Hematology, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Hospital Universitario Ramón y Cajal, 28034 Madrid, Spain.ORCID 0000-0003-2714-6731
José Ignacio Fernández-VelascoDepartment of Immunology, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Hospital Universitario Ramón y Cajal, 28034 Madrid, Spain.ORCID 0000-0001-9148-671X
Kyra Velázquez-KennedyDepartment of Hematology, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Hospital Universitario Ramón y Cajal, 28034 Madrid, Spain.
Eulalia Rodríguez-MartínDepartment of Immunology, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Hospital Universitario Ramón y Cajal, 28034 Madrid, Spain.ORCID 0000-0002-4924-6293
Alejandro Luna De AbiaDepartment of Hematology, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Hospital Universitario Ramón y Cajal, 28034 Madrid, Spain.ORCID 0000-0003-2201-3091
Ernesto RoldánDepartment of Immunology, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Hospital Universitario Ramón y Cajal, 28034 Madrid, Spain.
Gemma Moreno JiménezDepartment of Hematology, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Hospital Universitario Ramón y Cajal, 28034 Madrid, Spain.
Javier López-JiménezDepartment of Hematology, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Hospital Universitario Ramón y Cajal, 28034 Madrid, Spain.ORCID 0000-0002-2969-3002
Luisa María VillarDepartment of Immunology, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Hospital Universitario Ramón y Cajal, 28034 Madrid, Spain.ORCID 0000-0002-9067-3668
Roberto Pariente-RodríguezDepartment of Immunology, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Hospital Universitario Ramón y Cajal, 28034 Madrid, Spain.ORCID 0000-0001-9323-5236
Funding
Instituto Ramón y Cajal de Investigación Sanitaria PA22.PADI15 and PA23.IM_PADI10
6 · The paper itself
Abstract
Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL); however, a significant proportion of patients fail to achieve a durable response, underscoring the need for reliable predictive biomarkers. We characterize T-lymphocyte subpopulations in apheresis samples from 23 r/r large B-cell lymphoma (LBCL) patients who received axicabtagene ciloleucel (axi-cel) to identify pre-treatment cell biomarkers associated with CAR T-cell kinetics and clinical outcomes. Immunophenotyping of T-cells within fresh apheresis samples and monitoring of circulating CAR T-cells were performed by multiparametric flow cytometry. The median peak CAR T-cell count was 45.2 CAR T-cells/mL. Strong CAR-T expanders (≥45.2 CAR T-cells/mL) exhibited higher values of both CD4
Indexed as
CD8-Positive T-LymphocytesImmunotherapy, AdoptiveLeukocyte Common AntigensLymphoma, Large B-Cell, DiffuseReceptors, CCR7Receptors, Chimeric AntigenAdultAgedBiological ProductsBiomarkersBiomarkers, TumorBlood Component RemovalFemaleHumansImmunophenotypingMaleaxicabtagene ciloleucelBiological ProductsBiomarkersBiomarkers, TumorCCR7 protein, humanLeukocyte Common AntigensReceptors, CCR7Receptors, Chimeric AntigenapheresisbiomarkersCAR-Tcentral memory T-cellsdiffuse large B-cell lymphomaflow cytometry
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.